Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 175.58 USD 2.37% Market Closed
Market Cap: 310.3B USD
Have any thoughts about
Abbvie Inc?
Write Note

Net Margin
Abbvie Inc

9.2%
Current
15%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
9.2%
=
Net Income
5.1B
/
Revenue
55.5B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Abbvie Inc
NYSE:ABBV
310.3B USD
9%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
133.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36.2B EUR
-14%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
31.6B USD
-16%
Country US
Market Cap 310.3B USD
Net Margin
9%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 141.6B USD
Net Margin
13%
Country US
Market Cap 115.3B USD
Net Margin
0%
Country US
Market Cap 102.4B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 133.7B AUD
Net Margin
18%
Country US
Market Cap 77.3B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36.2B EUR
Net Margin
-14%
Country US
Market Cap 31.6B USD
Net Margin
-16%
No Stocks Found

Abbvie Inc
Glance View

Market Cap
310.3B USD
Industry
Biotechnology
Economic Moat
Wide

AbbVie Inc., a leader in the pharmaceutical industry, emerged from its parent company Abbott Laboratories in 2013, with a mission centered around addressing some of the world’s most complex and serious diseases. At its core, AbbVie is a research-driven entity that leverages scientific innovation to develop advanced therapies. With a robust pipeline, the company focuses on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, and women's health. It has developed a diversified portfolio designed to tackle challenging health issues. The company devotes significant resources to research and development, fostering a culture that celebrates scientific discovery as a pathway to improving patient lives worldwide. Revenue generation for AbbVie is deeply intertwined with its treatment offerings, particularly its lineup of blockbuster drugs. The flagship product, Humira, an anti-inflammatory medication, has consistently stood as one of the top-selling drugs globally. Despite facing patent expirations for Humira, AbbVie has strategically navigated this challenge through its robust product pipeline, which includes promising medicines like Skyrizi and Rinvoq in immunology. The company also expanded its revenue potential significantly with the acquisition of Allergan in 2020, adding Botox and other products in aesthetics and eye care to its portfolio. The calculated diversification of revenue streams ensures AbbVie maintains a competitive edge, securing its position as a formidable player in the pharmaceutical industry.

ABBV Intrinsic Value
150.06 USD
Overvaluation 15%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
9.2%
=
Net Income
5.1B
/
Revenue
55.5B
What is the Net Margin of Abbvie Inc?

Based on Abbvie Inc's most recent financial statements, the company has Net Margin of 9.2%.